158 related articles for article (PubMed ID: 38070040)
21. PROLONG-9FP clinical development program--phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).
Santagostino E
Thromb Res; 2013 Mar; 131 Suppl 2():S7-10. PubMed ID: 23537724
[TBL] [Abstract][Full Text] [Related]
22. Eftrenonacog Alfa: A Review in Haemophilia B.
Lamb YN; Hoy SM
Drugs; 2023 Jun; 83(9):807-818. PubMed ID: 37081241
[TBL] [Abstract][Full Text] [Related]
23. High adherence to prophylaxis regimens in haemophilia B patients receiving rIX-FP: Evidence from clinical trials and real-world practice.
Mancuso ME; Oldenburg J; Boggio L; Kenet G; Chan A; Altisent C; Seifert W; Santagostino E
Haemophilia; 2020 Jul; 26(4):637-642. PubMed ID: 32542961
[TBL] [Abstract][Full Text] [Related]
24. In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients.
Preijers T; van Spengler MWF; Meijer K; Fijnvandraat K; Fischer K; Leebeek FWG; Cnossen MH; Mathôt RAA
Eur J Clin Pharmacol; 2022 Feb; 78(2):237-249. PubMed ID: 34651201
[TBL] [Abstract][Full Text] [Related]
25. Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B.
Mancuso ME; Lubetsky A; Pan-Petesch B; Lissitchkov T; Nagao A; Seifert W; Li Y; Santagostino E
J Thromb Haemost; 2020 May; 18(5):1065-1074. PubMed ID: 32078256
[TBL] [Abstract][Full Text] [Related]
26. Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years.
Shapiro A; Chaudhury A; Wang M; Escobar M; Tsao E; Barnowski C; Feng J; Jain N; Quon DV
Haemophilia; 2020 Nov; 26(6):975-983. PubMed ID: 33012060
[TBL] [Abstract][Full Text] [Related]
27. Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy.
Oldenburg J; Yan S; Maro G; Krishnarajah G; Tiede A
Curr Med Res Opin; 2020 Jan; 36(1):9-15. PubMed ID: 31469321
[No Abstract] [Full Text] [Related]
28. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
Toby GG; Liu T; Buyue Y; Zhang X; Bitonti AJ; Pierce GF; Sommer JM; Jiang H; Peters RT
PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
[TBL] [Abstract][Full Text] [Related]
29. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.
Nolte MW; Nichols TC; Mueller-Cohrs J; Merricks EP; Pragst I; Zollner S; Dickneite G
J Thromb Haemost; 2012 Aug; 10(8):1591-9. PubMed ID: 22726310
[TBL] [Abstract][Full Text] [Related]
30. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
Powell JS; Apte S; Chambost H; Hermans C; Jackson S; Josephson NC; Mahlangu JN; Ozelo MC; Peerlinck K; Pasi J; Perry D; Ragni MV; Wang X; Jiang H; Li S; Cristiano LM; Innes A; Nugent K; Brennan A; Luk A; Allen G; Pierce GF; Robinson B
Br J Haematol; 2015 Jan; 168(1):124-34. PubMed ID: 25208598
[TBL] [Abstract][Full Text] [Related]
31. IDEAL study: A real-world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX-FP) in patients with haemophilia B in Italy.
Tagliaferri A; Molinari AC; Peyvandi F; Coppola A; Demartis F; Biasoli C; Borchiellini A; Cultrera D; De Cristofaro R; Daniele F; Giordano P; Marchesini E; Margaglione M; Marino R; Pollio B; Radossi P; Santoro C; Santoro RC; Siragusa S; Sottilotta G; Tosetto A; Piscitelli L; Villa MR; Zanon E; Finardi A; Schiavetti I; Vaccari D; Castaman G
Haemophilia; 2023 Jan; 29(1):135-144. PubMed ID: 36423202
[TBL] [Abstract][Full Text] [Related]
32. Switching and increasing prophylaxis regimen with a genetically recombinant fusion of coagulation factor IX and albumin in haemophilia B: a case report.
Álvarez-Román MT; Merchán RD; Mellado RCR; Jiménez-Yuste V
Curr Opin Hematol; 2023 Sep; 30(5):175-179. PubMed ID: 37522479
[TBL] [Abstract][Full Text] [Related]
33. Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort.
O'Donovan M; Bergin C; Quinn E; Singleton E; Roche S; Benson J; Bird R; Byrne M; Duggan C; Gilmore R; Ryan K; O'Donnell JS; O'Connell NM
Haemophilia; 2021 Jul; 27(4):618-625. PubMed ID: 33939224
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.
Négrier C; Abdul Karim F; Lepatan LM; Lienhart A; López-Fernández MF; Mahlangu J; Pabinger I; Li Y; Wolko D; Voigt C; Jacobs I; Santagostino E
Haemophilia; 2016 Jul; 22(4):e259-66. PubMed ID: 27333467
[TBL] [Abstract][Full Text] [Related]
35. Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B.
Shapiro AD; Kulkarni R; Ragni MV; Chambost H; Mahlangu J; Oldenburg J; Nolan B; Ozelo MC; Foster MC; Willemze A; Barnowski C; Jain N; Winding B; Dumont J; Lethagen S; Barnes C; Pasi KJ
Blood Adv; 2023 Jul; 7(13):3049-3057. PubMed ID: 36848635
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials.
Mancuso ME; Eriksson D; Falk A; Hakimi Z; Wojciechowski P; Wdowiak M; Klamroth R
J Blood Med; 2023; 14():427-434. PubMed ID: 37534261
[TBL] [Abstract][Full Text] [Related]
37. Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study.
Pasi KJ; Fischer K; Ragni M; Kulkarni R; Ozelo MC; Mahlangu J; Shapiro A; P'Ng S; Chambost H; Nolan B; Bennett C; Matsushita T; Winding B; Fruebis J; Yuan H; Rudin D; Oldenburg J
Haemophilia; 2020 Nov; 26(6):e262-e271. PubMed ID: 32497409
[TBL] [Abstract][Full Text] [Related]
38. Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B.
Martinowitz U; Lubetsky A
Thromb Res; 2013 Mar; 131 Suppl 2():S11-4. PubMed ID: 23537721
[TBL] [Abstract][Full Text] [Related]
39. External quality assessment for one-stage and chromogenic factor IX assays in samples containing Alprolix (rFIXFc) or Idelvion (rIX-FP) and evidence that UK National External Quality Assessment Scheme for blood coagulation samples are commutable with patient samples.
Kitchen S; Bowyer A; Lowe A; Jennings I; Walker ID
Int J Lab Hematol; 2022 Jun; 44(3):619-625. PubMed ID: 35040275
[TBL] [Abstract][Full Text] [Related]
40. Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B.
Pasi KJ; Fischer K; Ragni M; Nolan B; Perry DJ; Kulkarni R; Ozelo M; Mahlangu J; Shapiro AD; Baker RI; Bennett CM; Barnes C; Oldenburg J; Matsushita T; Yuan H; Ramirez-Santiago A; Pierce GF; Allen G; Mei B
Thromb Haemost; 2017 Feb; 117(3):508-518. PubMed ID: 28004057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
